



# Selective Randomization Inference for Adaptive Studies

Tobias Freidling<sup>1</sup> Qingyuan Zhao<sup>1</sup> Zijun Gao<sup>2</sup>

<sup>1</sup>University of Cambridge <sup>2</sup>University of Southern California



## Analysing Adaptive Studies




### Adaptive Studies

- Characteristics: Recruitment, treatment assignment and null hypothesis can depend on data from previous stages
- Benefits: reacting to external circumstances, more ethical treatment allocation, saving time and money [1]

### Data Analysis

- Difficulty: data informs design and null hypothesis → **risk of double dipping**
- Existing methods: design-specific, strong assumptions
- Our approach:** randomization inference → **no modelling assumptions or i.i.d. data needed**

## DAG and Notation



- Covariates  $X$  and potential outcomes  $Y(\cdot)$  of population
- Recruitment:**  $R_1, R_2$
- Treatment assignment:  $Z_1, Z_2$
- Observed outcomes:  $Y_{R_i} = Y_{R_i}(Z_i)$
- Selective choice:**  $S_1, S_2$
- Short-hand:  $W = (R, X_R, Y_R(\cdot))$



## Simulation Study

- 2 stages, 2 treatments  $Z_i \in \{0, 1\}$ , 2 groups  $X_i \in \{0, 1\}$
- Potential outcomes:  $Y_i(0) = Y_i(1) \sim N(0, 1)$  i.i.d.
- First stage: 50 patients
- $\Delta$  = standardized difference in SATEs between groups
- Selection variable and recruitment in second stage:

$$S = \begin{cases} 0, & \Delta < \Phi^{-1}(0.2), \\ 1, & \Delta > \Phi^{-1}(0.8), \\ 2, & \text{otherwise,} \end{cases} \quad \begin{array}{l} \text{recruit 25 from group } X_i = 0, \\ \text{recruit 25 from group } X_i = 1, \\ \text{recruit 13/12.} \end{array}$$

### Power analysis:

- Type-I error control overall and in subgroups
- More powerful than data splitting
- Similar approximations for rejection sampling and MCMC



## Selective Randomization P-value

**Insight:** only use randomness of  $Z$  as its distribution is known

Testing the null hypothesis

$$H_0: Y_i(1) - Y_i(0) = 0 \quad \text{for all } i \in R \text{ (or a subset)}$$

with the statistic  $T$ . ( $Z^* \stackrel{D}{=} Z$  and  $Z^* \perp\!\!\!\perp Z \mid W$ )

- Usual randomization p-value<sup>[2]</sup>: **invalid due to double dipping**  
 $P^*(T(Z^*, W) \leq T(Z, W) \mid Z, W)$
- Data splitting<sup>[3]</sup> / 2<sup>nd</sup> stage randomization p-value: **loses power**  
 $P^*(T(Z^*, W) \leq T(Z, W) \mid Z, W, Z_1^* = Z_1)$
- Selective randomization p-value:** valid & more powerful [4, 5]  
 $p(Z) := P^*(T(Z^*, W) \leq T(Z, W) \mid Z, W, S(Z_1^*) = S(Z_1))$

## Inference and Computation

Inference for a homogeneous treatment effect  $\beta = Y_i(1) - Y_i(0)$ , where  $i \in R$  (or a subset):

- $(1 - \alpha)$  confidence interval: **inversion of tests**  $\{\beta: p_\beta(Z) \geq \alpha\}$
- Estimation:  $\hat{\beta} = \beta$  such that  $p_\beta(Z) = 0.5$

Computation of p-value via **Monte Carlo approximation**

$$\frac{\sum_{j=1}^m \mathbf{1}\{T(z_j^*, W) \leq T(Z, W)\} \cdot P^*(Z^* = z_j^* \mid W)}{\sum_{i=1}^m P^*(Z^* = z_i^* \mid W)},$$

where sample  $(z_j^*)_{j=1}^m$  is generated via **rejection sampling or MCMC**

## References

- Philip Pallmann, Alun W. Bedding, Babak Choodari-Oskooei, and collab. Adaptive designs in clinical trials: why use them, and how to run and report them. *BMC Medicine*, 16(1):29, 2018.
- R. A. Fisher. *The design of experiments*. Oliver & Boyd, Edinburgh, 1935.
- D. R. Cox. A note on data-splitting for the evaluation of significance levels. *Biometrika*, 62(2):441-444, 1975.
- Yao Zhang and Qingyuan Zhao. What is a Randomization Test? *Journal of the American Statistical Association*, 0(0):1-15, 2023.
- William Fithian, Dennis Sun, and Jonathan Taylor. Optimal Inference After Model Selection. *arXiv*: 1410.2597, 2017.